The analysis of peripheral blood and tumor tissue specimens in patients receiving anti-PD-1, anti-CTLA-4, or the combinatorial therapy demonstrated that CTLA-4 blockade induced a proliferative signature in a subset of memory T cells. This evidence concerns the gene PDCD1 and neoplasm.